3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
3
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
venetoclax
15
ibrutinib
12
Rituximab
10
Cyclophosphamide
10
obinutuzumab
9
acalabrutinib
8
Specimen Handling
8
Biopsy
7
pirtobrutinib
6
zanubrutinib
5
fludarabine phosphate
4
fludarabine
4
Whole-Body Irradiation
4
Magnetic Resonance Spectroscopy
4
Lenalidomide
4
ARQ531
4
idelalisib
3
Vincristine
3
Prednisone
3
Doxorubicin
3
Cyclosporine
3
Bendamustine Hydrochloride
3
Sirolimus
2
Peripheral Blood Stem Cell Transplantation
2
Mycophenolic Acid
2
CT-P10
2
treosulfan
1
tocilizumab
1
pembrolizumab
1
mirdametinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Lymphocytic, Chronic, B-Cell
×
R-CHOP protocol
×
30 days
×
Clear all
NCT04542824
2026-06-02
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2
Active not recruiting
78 enrolled